Stock XERS XERIS BIOPHARMA HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Xeris Biopharma Holdings, Inc.

Equities

XERS

US98422E1038

Real-time Estimate Cboe BZX
Other stock markets
 03:55:31 2024-05-28 pm EDT 		5-day change 1st Jan Change
1.925 USD -0.26% Intraday chart for Xeris Biopharma Holdings, Inc. -4.00% -18.30%
May. 09 Transcript : Xeris Biopharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09 Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Xeris Biopharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024
Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M
MT
Xeris Biopharma: Q1 Earnings Snapshot
AQ
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
BU
Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2024
CI
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Xeris Biopharma Collaborating With Beta Bionics for Development, Commercialization of Glucagon Product
MT
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
BU
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
BU
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BU
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
BU
Oppenheimer Initiates Coverage on Xeris Biopharma With Outperform Rating, $5 Price Target
MT
Xeris Biopharma Holdings, Inc.(NasdaqGS:XERS) added to S&P Pharmaceuticals Select Industry Index
CI
Transcript : Xeris Biopharma Holdings, Inc., Q4 2023 Earnings Call, Mar 06, 2024
Xeris Biopharma: Q4 Earnings Snapshot
AQ
Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q4 Revenue $44.4M, vs. Street Est of $43.6M
MT
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
BU
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
BU
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Xeris Biopharma Holdings, Inc. Provides Earnings Guidance for the Year 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XERS Stock
  4. News Xeris Biopharma Holdings, Inc.